Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + etoposide + prednisone + vincristine
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of five drugs: cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), etoposide (a topoisomerase II inhibitor), prednisone (a synthetic glucocorticoid corticosteroid), and vincristine (a vinca alkaloid). The regimen is commonly referred to as CHOPE or CHOEP. It is used primarily in the treatment of advanced-stage Hodgkin lymphoma, non-Hodgkin lymphoma—including aggressive subtypes—and other hematologic malignancies. Each component acts via a distinct mechanism to inhibit cancer cell proliferation and survival: - Cyclophosphamide cross-links DNA strands, leading to apoptosis. - Doxorubicin intercalates into DNA and inhibits topoisomerase II. - Etoposide also inhibits topoisomerase II, causing DNA strand breaks. - Vincristine disrupts microtubule formation during mitosis. - Prednisone induces apoptosis in certain cancer cells through its glucocorticoid activity. The combination aims to maximize antitumor efficacy by targeting multiple pathways involved in cell division and survival[1][4][5].
- Brand names
- OncovinToposarCytoxanAdriamycinRituxanRuxienceTruximaRiabni
- Other names
- CHOPECHOEPI-CHOPE
02
Targets
DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + etoposide + prednisone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + etoposide + prednisone + vincristine.